The German pharmaceutical company Biontech plans to offer data on the inoculation against the coronavirus with its vaccine in children between five and 11 years old at the end of September. The dose for this age group will be 10 micrograms, a third of the adult dose, Özlem Türeci, co-founder of Biontech, said in statements published in Bild am Sonntag.

Biontech announced on September 10 that it will apply for approval of its coronavirus vaccine for children between the ages of five and eleven in the coming weeks. According to the report, the results of the study are already available and only need to be prepared for the regulatory authorities.

Vaccination data for even younger children will be available by the end of the year, according to Türeci. “(For that group) we will lower the dose again,” she added.

Risks prevention

For its part, the European Medicines Agency (EMA) stated that it could not yet give a deadline for a possible authorization. The German pharmaceutical company is already preparing production. The director of the German Pediatric Association, Jörg Dötsch, stressed that vaccination in the age group would especially benefit children at risk.

Dötsch added that Germany’s Standing Committee on Immunization (Stiko) could start by recommending vaccination at that age for children at risk, just as it did for children 12 to 17 years old. The risk of unexpected side effects must be weighed against the benefit of vaccination, he stressed.

Regarding booster vaccines, Ugur Sahin, co-founder of Biontech, commented that it depends on the desired strategy. “If you want to keep infections at a low level in general, you need a high level of antibodies to be able to prevent infections. For this purpose, the third vaccination makes sense.” But if you want to prevent serious diseases and the overflow of intensive care units, you can certainly follow a different strategy and wait longer for booster shots.”

Sahin was optimistic about the evolution of the pandemic in Germany. In his opinion, in the next European spring almost the entire population will be immune, either because it is vaccinated or because it was immunized after passing the infection. “The virus will still be there, but the strategies on how society deals with it will no longer be controversial. The virus will no longer be a threat.”

Source: dpa

La entrada Biontech plans to provide data on children’s vaccine by the end of September apareció primero en Bitfinance.

The German biotechnology company Biontech plans to develop a messenger RNA vaccine against malaria in the coming years, the pharmaceutical company announced today.

The firm plans to start a clinical trial in late 2022. An mRNA vaccine (mRNA stands for messenger ribonucleic acid.) teaches the body’s cells to produce a protein or a portion of a protein that triggers an immune response against the pathogen without having to come into contact with it.

Biontech has announced its intention to develop a safe and highly effective mRNA vaccine that generates long-lasting immunity for the prevention of malaria. In addition, the company is exploring the possibility of creating production facilities in Africa that can manufacture mRNA-based vaccines.

Malaria is one of the most dangerous infectious diseases in the world. In 2019, the WHO recorded 229 million cases and more than 400,000 deaths, most of them in children under the age of five. For decades, researchers have looked for a reliable vaccine, but so far none have been approved.

Source: dpa

La entrada Biontech plans to develop a vaccine against malaria apareció primero en Bitfinance.

The German company Biontech plans to develop together with the federal state of Bavaria software to improve the management of vaccine distribution.

Previously, the German magazine “Der Spiegel” reported on this and indicated that the computer system could also handle other vaccines in addition to those manufactured by Biontech in collaboration with its US partner Pfizer.

The information technology department of Biontech as well as an associated company are currently working on the project, according to the spokesperson.

According to Biontech, talks are being held with the German Ministry of Health for a possible collaboration on the project.

The purpose of the software is to improve the reliability of vaccination center planning and to help them react flexibly to any change in delivery quantities.

K. Tovar

Source: Grupo Provincia

La entrada Biontech will work to improve vaccine management apareció primero en Bitfinance.